Tourmaline Bio Inc (TRML)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 03-2025 | 12-2024 | 09-2024 | 06-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -46,062 | -22,970 | -73,210 | -50,975 | -30,798 |
| Depreciation Amortization | -2,973 | -1,550 | -7,555 | -5,592 | -3,451 |
| Accounts payable and accrued liabilities | -609 | -1,349 | 2,437 | 983 | 1,316 |
| Other Working Capital | 2,267 | 526 | -3,154 | -4,688 | -1,843 |
| Other Operating Activity | 5,434 | 3,664 | 4,219 | 3,898 | 1,846 |
| Operating Cash Flow | $-41,943 | $-21,679 | $-77,263 | $-56,374 | $-32,930 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | -9 | -9 | N/A | N/A |
| Purchase Of Investment | -125,618 | -85,164 | -366,136 | -346,445 | -258,400 |
| Sale Of Investment | 167,878 | 111,114 | 171,840 | 135,750 | 59,400 |
| Investing Cash Flow | $42,244 | $25,941 | $-194,305 | $-210,695 | $-199,000 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 623 | 569 | 161,352 | 161,352 | 161,352 |
| Common Stock Repurchased | -7 | -7 | -4 | -1 | N/A |
| Financing Cash Flow | $616 | $562 | $161,348 | $161,351 | $161,352 |
| Beginning Cash Position | 30,733 | 30,733 | 140,953 | 140,953 | 140,953 |
| End Cash Position | 31,650 | 35,557 | 30,733 | 35,235 | 70,375 |
| Net Cash Flow | $917 | $4,824 | $-110,220 | $-105,718 | $-70,578 |
| Free Cash Flow | |||||
| Operating Cash Flow | -41,943 | -21,679 | -77,263 | -56,374 | -32,930 |
| Capital Expenditure | -16 | -9 | -9 | 0 | N/A |
| Free Cash Flow | -41,959 | -21,688 | -77,272 | -56,374 | -32,930 |